Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for TRABECTEDIN
- Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working
- tTF-NGR Randomized Study - STS
- Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working
- Multicohort Trial of Trabectedin and Low-dose Radiation Therapy in Advanced/Metastatic Sarcomas
- Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma
- Reprab Study: PLD + Trabectedin Rechallenge
- Study on Trabectedin in Combination With Pioglitazone in Patients Myxoid Liposarcomas With Stable Disease After T Alone.
- Pemetrexed, Cisplatin With Soft Tissue Sarcoma
- Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Leiomyosarcoma
- Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma
- Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma
- Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma
- SARC037: A Phase I Study to Evaluate the Safety of Trabectedin in Combination With Irinotecan in Ewing Sarcoma Patients
- Prospective Identification of Predictive Biomarkers of Trabectedin Efficacy in Non-L Soft-tissue Sarcoma Patients
- Olaratumab Plus Trabectedin in Advanced Soft-tissue Sarcoma Patients Soft-tissue Sarcoma Patients
- Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma
- Trabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK Inhibitor
- Randomized Trial in Advanced, Metastatic or Unresectable Soft Tissue Sarcoma After Failure of Standard Treatments.
- Study on Leiomyosarcoma, Liposarcomas and Synovial Sarcoma With Trabectedin
- Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer
- Combined Treatment With Nivolumab and Trabectedin in Patients With Metastatic or Inoperable Soft Tissue Sarcomas
- NAPAGE: NAb-PAclitaxel and GEmcitabine in Advanced Soft Tissue Sarcoma
- Assessing the Combination of Durvalumab (MEDI4736) and Trabectedin in Solid Tumors
- Olaparib After Response to Trabectedin-pegylated Liposomal Doxorubicin in Recurrent Ovarian Carcinoma
- Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma
- Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma
- Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma.
- Comparison of QoL Between Trabectedin/PLD and Standard Platinum-based Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer
- SAINT:Trabectedin, Ipilimumab and Nivolumab as First Line Treatment for Advanced Soft Tissue Sarcoma
- Study of Olaparib/Trabectedin vs. Doctor's Choice in Solid Tumors
- Trabectedin Combined With Durvalumab in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Carcinomas.
- Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery
- Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma
- Study With Trabectedin Versus Adriamycin Plus Dacarbazine, in Patients With Advanced Solitary Fibrous Tumor
- Study Comparing Efficacy of Doxorubicin With Trabectedin Followed by Trabectedin Versus Doxorubicine in Patients With Leiomyosarcoma
- Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS)
- Trabectedin Maintenance Post 1st-line in STS
- Trial on Trabectedin (ET-743) vs Clinician's Choice Chemotherapy in Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancers of BRCA Mutated or BRCAness Phenotype Patients
- Non-interventional European Study of Trabectedin + PLD in the Treatment of Relapsed Ovarian Cancer (ROC) Patients
- Targeting Microenvironment and Cellular Immunity in Sarcomas Weekly Trabectedin Combined With Metronomic Cyclophosphamide
- Retrospective Study of Trabectedin in Soft Tissue Sarcomas
- Trial Comparing Trabectedin to the Best Supportive Care in Patients With Sarcoma
- Trabectedin and Irinotecan for Refractory Pediatric Sarcomas
- Trabectedin Plus Olaparib in Metastatic or Advanced Sarcomas (TOMAS)
- Retrospective Study to Analyze the Efficacy and Safety of Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), According to SmPC
- Efficacy and Safety of Trabectedin (Yondelis®) in Patients With Advanced Soft Tissue Sarcoma
- Hyper-Thermia Enhanced Anti-tumor Efficacy of Trabectedin
- Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients
- Activity of Trabectedin or Gemcitabine + Docetaxel in Uterine Leiomyosarcoma
- Efficacy Study on Trabectedin in Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma
- Trabectedin for Recurrent Grade II/III Meningioma
- ATREUS - Phase II Study on the Activity of Trabectedin in Patients With Malignant Pleural Mesothelioma (MPM)
- Ovarian Cancer Treatment Platinum-sensitive Relapse - Cohort Study (PROSPECTYON)
- Study of Doxorubicin and Trabectedin in First Line Treatment on Patients With Metastatic Leiomyosarcoma
- Trabectedin First Line Therapy In Unfit Sarcoma Study
- Phase II Study of Regorafenib in Metastatic Soft Tissue Sarcoma
- A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Study With Trabectedin in BRCA1 and BRCA2 Mutation Carrier and BRCAness Phenotype Ovarian Cancer
- Bevacizumab and Trabectedin +/- Carboplatin in Advanced Ovarian Cancer
- Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy
- A Study of Trabectedin (YONDELIS) in Patients With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma
- Activity and Tolerability of Pazopanib in Advanced and/or Metastatic Liposarcoma. A Phase II Clinical Trial
- Tabectedin to Treat Children and Adolescents With Cancer
- YONDELIS (Trabectedin) Single Patient Compassionate Use / Expanded Access
- Combination Therapy of Gemcitabine and Trabectedin in L-sarcomas
- INOVATYON STUDY -International, Randomized Study in Patients With Ovarian Cancer
- A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma
- Trabectedin in Treating Patients With Metastatic Pancreatic Cancer After First-Line Chemotherapy
- Continuing vs Intermittent Trabectedin in Patients With Advanced Soft Tissue Sarcoma
- A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic Dysfunction
- A Study to Assess the Potential Effects of Rifampin on the Pharmacokinetics of Trabectedin in Patients With Advanced Malignancies
- A Study to Assess the Potential Effects of Ketoconazole on the Pharmacokinetics of Trabectedin in Patients With Advanced Malignancies
- Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma
- Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure
- Doxorubicin vs. Trabectedin Plus Doxorubicin in Non Operable and/or Metastatic STS
- An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS)
- A Study to Assess the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the Electrocardiogram
- An Efficacy Study of Trabectedin in the Treatment of Participants With Specific Subtypes of Metastatic Breast Cancer
- Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid / Round Cell Liposarcoma
- Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer
- Trabectedin in Treating Patients With Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus
- A Study to Provide Access to Trabectedin in Participants With Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Persistent or Recurrent Disease and Who Are Not Expected to Benefit From Currently Available Standard of Care Treatment
- ET 743 (Yondelis) in Men With Advanced Prostate Cancer
- An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer
- A Safety Study Utilizing Yondelis and Doxorubicin in Patients With a Type of Cancer Called Soft Tissue Sarcoma
- A Phase 2 Study of Trabectedin (Yondelis) in Adult Male Participants With Advanced Prostate Cancer
- Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors
- A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer
- Phase 2 Study of ET-743 (Trabectedin) in Patients With Persistent or Recurrent Endometrial Carcinoma
- A Study of ET-743 (Trabectedin) in Patients With Advanced Breast Cancer
- A Study of Trabectedin in Patients With Advanced Ovarian Cancer
- Ecteinascidin 743 in Treating Patients With Malignant Mesothelioma
- Ecteinascidin 743 in Treating Patients With Unresectable Advanced or Metastatic Soft Tissue Sarcoma
- Ecteinascidin 743 in Treating Patients With Previously Treated Metastatic Osteosarcoma
- Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma
- Ecteinascidin 743 in Treating Adults With Advanced Solid Tumors
Clinical trials list
click for details